tradingkey.logo
搜索

ImmuCell Corp

ICCC
添加自选
10.290USD
-0.710-6.45%
收盘 07/02, 13:00美东报价延迟15分钟
93.09M总市值
亏损市盈率 TTM

ImmuCell Corp

10.290
-0.710-6.45%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-6.45%

5天

+5.11%

1月

+6.41%

6月

+67.32%

今年开始到现在

+67.32%

1年

+55.44%

关键数据
10.930今开
10.930最高
41.07K成交量
亏损市盈率 TTM
--市盈率动
--股息TTM
0.45%换手率
11.000昨收
10.070最低
289.75K成交额
亏损市盈率静
3.20市净率
0.00%股息率 TTM
-1.22%ROA
10.75052周最高
2.02量比
-2.16M净利润
9.05M总股本
-0.0617每股收益TTM
0.54Beta
-1.88%ROE
4.52052周最低
7.82%振幅
44.97%毛利率
93.09M总市值
3.17回报/风险
2.98%风险率

TradingKey ImmuCell Corp股票评分

单位: USD 更新时间: 2026-07-01

操作建议

ImmuCell Corp当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在药品行业排名102/157位。机构持股占比非常高,中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

ImmuCell Corp评分

相关信息

行业排名
102 / 157
全市场排名
303 / 4564
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

ImmuCell Corp亮点

亮点风险
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
业绩高增长
公司营业收入稳步增长,连续3年增长58.22%
业绩增长期
公司处于发展阶段,最新年度总收入27.64M美元
估值低估
公司最新PE估值-178.28,处于3年历史低位
机构加仓
最新机构持股2.16M股,环比增加9.59%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值0.00

分析师目标

根据 0 位分析师
--
评级
--
目标均价
--
涨幅空间

ImmuCell Corp新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

ImmuCell Corp简介

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
公司代码ICCC
公司ImmuCell Corp
CEOte Boekhorst (Olivier)
网址https://immucell.com/

常见问题

ImmuCell Corp(ICCC)的当前股价是多少?

ImmuCell Corp(ICCC)的当前股价是 11.00。

ImmuCell Corp的股票代码是什么?

ImmuCell Corp的股票代码是ICCC。

ImmuCell Corp股票的52周最高点是多少?

ImmuCell Corp股票的52周最高点是10.75。

ImmuCell Corp股票的52周最低点是多少?

ImmuCell Corp股票的52周最低点是4.52。

ImmuCell Corp的市值是多少?

ImmuCell Corp的市值是99.51M。

ImmuCell Corp(ICCC)股票的每股收益(EPS TTM)是多少

ImmuCell Corp(ICCC)股票的每股收益(EPS TTM)是-0.12。